Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-11-07
2006-11-07
Huff, Sheela J. (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S013800, C514S014800, C514S015800, C514S016700
Reexamination Certificate
active
07132400
ABSTRACT:
The subject invention addresses the need for methods of treatment and prevention of breast cancer, and other cancers, by providing a peptide of eight to twenty amino acids in length which comprises a hydrophilic analog of an alpha-fetoprotein peptide having SEQ ID NO:6: EMTPVNPG. The peptides may be linear, but are preferably cyclic. The peptides may be provided as dimers or other multimers. A composition comprising the peptide, an antibody that specifically binds to the peptide, a method of reducing estrogen-stimulated growth of cells using the peptide, as well as a method of treating or preventing cancer, such as breast cancer, are also provided. The treatment or prevention method can include the use of tamoxifen therapy in combination with the peptide therapy.
REFERENCES:
patent: 5674842 (1997-10-01), Mizejewski
patent: 5707963 (1998-01-01), Mizejewski
patent: 6306832 (2001-10-01), Pietras
Gura Science vol. 273 p. 1041 (1997).
Burgess et al, Journal of Cell Biology vol. 111 Nov. 1990 2129-2138.
Lazar et al Molecular and Cellular Biology Mar. 1988 vol. 8 No. 3 1247-1252.
Bennett, et al. (2001). Abstract Only “An α-fetoprotein-Derived Peptide Inhibits Estrogen Receptor Positive Breast Cancers, Sensitive and Resistant to Tamoxifen”Proc. Amer. Assoc. Can. Res.42: 238.
Eisele, et al. (2001).J. Pept. Res.57:29-38.
Eisele, et al. (2001).J. Pept. Res.57:539-546.
Gekonge, et al. (2001). Abstract OnlyProc. Amer. Assoc. Can. Res.42: 239.
Jacobson, et al. (2000). Abstract from International Society for Preventive Oncology (ISPO) Meeting, Oct. 28-Oct. 31, 2000, http://www.cancerprev.org/Meetings/2000/Abstracts/ Show?Num=556.
Mesfin, et al. (2000).Biochim. Et. Biophys. Act.1501: 33-43.
Mesfin, et al. (2000).Abstract OnlyProc. Amer. Assoc. Can Res.41: 375.
Mesfin, et al. (2001). Abstract OnlyProc. Amer. Assoc. Can. Res42: 778.
Mesfin, et al. (2001).J. Pept. Res.58: 246-256.
Mizejewski, et al. (1996).Molec. Cell. Endo.118:15-23.
Vakharia, et al. (2000). Abstract Only.Breast Can. Res. Treat.63:41-52.
Duphinee, et al. (2000). Abstract Only.Breast. Can. Res. Treat64:109.
MacColl, et al. (2001). Abstract Only.Biochim. Biophys. ACTA Gen. Subj.1528(2-3): 127-134.
Li, et al. (2001). Abstract Only.Clin. Chim. ACTA313:15-19.
Andersen Thomas T.
Bennett James A.
Jacobson Herbert I.
Mesfin Fassil B.
Biswas, Esq. Naomi S.
CLF Medical Technology Acceleration Program, Inc.
Elrifi, Esq. Ivor R.
Huff Sheela J.
Mintz Levin
LandOfFree
Alpha-fetoprotein peptides and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alpha-fetoprotein peptides and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha-fetoprotein peptides and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3659528